What is the appropriate treatment for a patient with insulin resistance, fasting glucose of 132 mg/dL, elevated fasting insulin, and BMI ≥ 25 kg/m²?

Treatment for Insulin Resistance

For a patient with insulin resistance, fasting glucose of 132 mg/dL, elevated fasting insulin, and BMI ≥25 kg/m², initiate metformin as first-line pharmacotherapy combined with lifestyle modification targeting 5-7% weight loss and 150 minutes weekly of moderate physical activity 1.

Pharmacologic Management

First-Line: Metformin

Metformin is the cornerstone pharmacologic treatment for insulin resistance and impaired fasting glucose (your patient's fasting glucose of 132 mg/dL exceeds the normal threshold of 100-125 mg/dL for impaired fasting glucose) 1, 2. The 2025 ADA Standards prioritize metformin because it:

• Reduces cardiovascular mortality (superior to sulfonylureas)
• Is weight-neutral (critical given your patient's BMI ≥25)
• Does not cause hypoglycemia
• Directly improves insulin sensitivity
• Is inexpensive and widely available 1

Dosing strategy: Start with extended-release formulation to minimize gastrointestinal side effects (bloating, diarrhea). Titrate gradually to therapeutic dose 1.

Critical monitoring: Check vitamin B12 levels periodically, as metformin increases deficiency risk and can worsen neuropathy symptoms 1.

When to Escalate Beyond Metformin

If A1C remains ≥1.5% above goal after 3-6 months on metformin, consider dual-combination therapy 1. However, your patient's presentation (fasting glucose 132 mg/dL without mention of severe hyperglycemia symptoms) does not warrant immediate insulin initiation. Reserve insulin for:

• Blood glucose ≥300 mg/dL
• A1C >10%
• Catabolic features (weight loss, ketosis, hypertriglyceridemia) 1

Lifestyle Interventions (Non-Negotiable)

Weight Loss Target

Achieve 5-7% body weight reduction through structured dietary modification 2. This is not optional—it's as effective as pharmacotherapy and addresses the root pathophysiology.

Physical Activity Prescription

150 minutes per week of moderate-intensity exercise 2. This directly improves peripheral insulin sensitivity in muscle tissue.

Dietary Pattern Selection

The evidence hierarchy for insulin resistance:

1. Mediterranean diet (strongest evidence): Most consistent HOMA-IR reductions, 31% decrease in type 2 diabetes incidence, proven efficacy across metabolic conditions 3

2. Low-glycemic index diet: Improves postprandial insulin dynamics, particularly effective when BMI ≥25 3

3. Intermittent fasting: Meta-analysis shows significant reductions in BMI (-0.75 kg/m²), fasting glucose (-4.16 mg/dL), and HOMA-IR (-0.54), with improved adiponectin and leptin profiles 4. However, a 7-18 day therapeutic fasting study showed only 15% maintained HOMA-IR improvement at 80-day follow-up, suggesting sustainability challenges 5

Practical recommendation: Start with Mediterranean diet as the evidence base is most robust for long-term adherence and metabolic outcomes 3.

Pathophysiologic Considerations

Your patient's elevated fasting insulin with fasting glucose of 132 mg/dL indicates compensatory hyperinsulinemia attempting to overcome peripheral insulin resistance 6. The BMI ≥25 suggests fat mass and waist circumference are driving insulin hypersecretion through:

• Hepatic glucose overproduction (rightward shift in dose-response curve)
• Elevated free fatty acids interfering with insulin signaling
• Chronic low-grade inflammation 6, 7

Sex matters: If your patient is male, the effect of adiposity on insulin secretion is more pronounced, requiring more aggressive intervention 6.

Common Pitfalls to Avoid

1. Don't delay metformin initiation: Waiting for "lifestyle modification alone" wastes time during which insulin resistance worsens and beta-cell function declines

2. Don't use thiazolidinediones as first-line: Despite their insulin-sensitizing effects 8, they cause weight gain—counterproductive when BMI is already ≥25

3. Don't ignore renal function: Metformin is safe with eGFR ≥30 mL/min/1.73 m², but requires dose adjustment or discontinuation if eGFR 30-45 mL/min/1.73 m² 1

4. Don't prescribe sulfonylureas: They cause hypoglycemia and weight gain, worsening the underlying problem 1

Monitoring Strategy

• Reassess every 3-6 months with A1C and fasting glucose 1
• HOMA-IR can track insulin resistance improvement (though hyperinsulinemic-euglycemic clamp is gold standard, it's impractical clinically) 7
• Weight and waist circumference at each visit—fat mass is the strongest predictor of insulin secretion 6